Your browser doesn't support javascript.
loading
Imaging for Oncologic Response Assessment in Lymphoma.
Kulkarni, Naveen M; Pinho, Daniella F; Narayanan, Srikala; Kambadakone, Avinash R; Abramson, Jeremy S; Sahani, Dushyant V.
Afiliación
  • Kulkarni NM; 1 Division of Abdominal Imaging, Medical College of Wisconsin, Milwaukee, WI.
  • Pinho DF; 2 University of Texas Southwestern Medical Center, Dallas, TX.
  • Narayanan S; 3 Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA.
  • Kambadakone AR; 4 Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, White 270, Boston, MA 02114.
  • Abramson JS; 5 Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Sahani DV; 4 Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, White 270, Boston, MA 02114.
AJR Am J Roentgenol ; 208(1): 18-31, 2017 Jan.
Article en En | MEDLINE | ID: mdl-27786547
OBJECTIVE: The purpose of this article is to examine the role of different imaging biomarkers, focusing in particular on the use of updated CT and PET response criteria for the assessment of oncologic treatment effectiveness in patients with lymphoma but also discussing other potential functional imaging methods and their limitations. CONCLUSION: Lymph nodes are commonly involved by metastatic solid tumors as well as by lymphoma. Evolving changes in cancer therapy for lymphoma and metastases have led to improved clinical outcomes. Imaging is a recognized surrogate endpoint that uses established criteria based on changes in tumor bulk to monitor the effects of treatment. With the introduction of targeted therapies and novel antiangiogenic drugs, the oncologic expectations from imaging assessment are changing to move beyond simple morphologic methods. Molecular and functional imaging methods (e.g., PET, perfusion, DWI, and dual-energy CT) are therefore being investigated as imaging biomarkers of response and prognosis. The role of these advanced imaging biomarkers extends beyond measuring tumor burden and therefore might offer insight into early predictors of therapeutic response. Despite the potential benefits of these exciting imaging biomarkers, several challenges currently exist.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tomografía Computarizada por Rayos X / Evaluación de Resultado en la Atención de Salud / Imagen de Difusión por Resonancia Magnética / Tomografía de Emisión de Positrones / Linfoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: AJR Am J Roentgenol Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tomografía Computarizada por Rayos X / Evaluación de Resultado en la Atención de Salud / Imagen de Difusión por Resonancia Magnética / Tomografía de Emisión de Positrones / Linfoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: AJR Am J Roentgenol Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos